McKesson Corporation $MCK Shares Bought by Assetmark Inc.

Assetmark Inc. grew its stake in shares of McKesson Corporation (NYSE:MCK) by 32.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 26,991 shares of the company’s stock after buying an additional 6,609 shares during the quarter. Assetmark Inc.’s holdings in McKesson were worth $20,851,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. J.W. Cole Advisors Inc. increased its stake in shares of McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after purchasing an additional 1,329 shares during the period. Private Wealth Partners LLC raised its stake in McKesson by 5.6% during the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after acquiring an additional 1,682 shares in the last quarter. AlphaQuest LLC raised its stake in McKesson by 91.2% during the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock valued at $1,365,000 after acquiring an additional 843 shares in the last quarter. CW Advisors LLC boosted its position in McKesson by 282.5% during the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after acquiring an additional 8,130 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in shares of McKesson by 12.4% in the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after purchasing an additional 36,451 shares in the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Stock Performance

Shares of NYSE:MCK opened at $933.75 on Friday. The stock has a market capitalization of $114.37 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 1.50 and a beta of 0.40. McKesson Corporation has a 1-year low of $585.22 and a 1-year high of $971.93. The company has a 50 day moving average price of $840.13 and a 200 day moving average price of $788.06.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, sell-side analysts expect that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a $0.82 dividend. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 9.43%.

Insider Transactions at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,851,096.24. This represents a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a report on Thursday, January 29th. Robert W. Baird set a $968.00 price target on shares of McKesson in a research report on Wednesday, January 14th. Zacks Research lowered shares of McKesson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Barclays initiated coverage on shares of McKesson in a research note on Monday, December 8th. They set an “overweight” rating and a $960.00 price objective on the stock. Finally, Weiss Ratings cut McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $937.07.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.